Efficacy and toxicity of drugs targeting KRAS G12C mutation in non-small cell lung cancer: a meta-analysis.
Wei LuoJing ZhuWenxue ZhangAiru YuWei ZhouKe XuPublished in: Expert review of anticancer therapy (2023)
mutation NSCLC, have definite efficacy and acceptable safety, especially for patients with advanced or metastatic disease and within posterior line therapy.